A New Hope in Alzheimer's Disease Psychosis: Pimavanserin

Kurhan F., Akın M.

Current Alzheimer Research, vol.20, no.6, pp.403-408, 2023 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 20 Issue: 6
  • Publication Date: 2023
  • Doi Number: 10.2174/1567205020666230825124922
  • Journal Name: Current Alzheimer Research
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE, Psycinfo
  • Page Numbers: pp.403-408
  • Keywords: Alzheimer´s disease, antipsychotic, dementia, Parkinson's psychosis, pimavanserin, psychosis
  • Van Yüzüncü Yıl University Affiliated: Yes


Alzheimer's disease (AD) ranks first among the causes of dementia worldwide. AD can develop a psychotic manifest at a significant rate. AD prognosis worsens by added psychosis clin-ic. There is no treatment approved by the United States Food and Drug Administration (FDA) among antipsychotics for Alzheimer’s disease Psychosis (ADP). However, pimavanserine, an atypical antipsychotic, has been approved by the FDA for Parkinson's psychosis. It is predicted that pi-mavanserin, a new antipsychotic, will fill an important gap in this area. In clinical trials, it appears to be effective in the treatment of delusions and hallucinations at psychosis in both Parkinson's and AD. In this systematic review, we evaluated the analysis of current literature data on pimavanserin used in ADP. We searched the existing literature on clinical studies on pimavanserin therapy used in ADP. Data were determined by systematically searching PubMed, MEDLINE, EMBASE, and Google Scholar until December 2022. A total of 35 citations were found and uploaded on the Men-deley program. Abstracts and full texts of literature data were examined. Pimavanserin was ob-served, and satisfactory results were obtained in treating ADP. Pimavanserin has a unique mechanism of action. Pimavanserin, an atypical antipsychotic drug, has a low affinity for 5-HT2C receptors and has selective 5-HT2A reverse agonist/antagonist action. Pimavanserin has no clinically significant affinity for dopaminergic, histaminergic, muscarinic or adrenergic receptors. This agent may also achieve significant positive results in resistant psychosis treatments.